Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study

References

• WhitingDRGuariguataLWeilCShawJIDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030Diabetes Res Clin Pract20119431132122079683
   PubMed Web of Science ®Google Scholar
• MajeedAEl-SayedAAKhojaTAlshamsanRMillettCRawafSDiabetes in the Middle-East and North Africa: an update for 2013 for the IDF Diabetes AtlasDiabetes Res Clin Pract201410321822224300017
   PubMed Web of Science ®Google Scholar
• AlhyasLMcKayABalasanthiranAMajeedAQuality of type 2 diabetes management in the states of the Cooperation Council for the Arab States of the Gulf: a systematic reviewPLoS One20116e2218621829607
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes: a patient-centered approachDiabetes Care2012351364137922517736
   PubMed Web of Science ®Google Scholar
• BalasBBaigMRWatsonCThe dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single dose administration in type 2 diabetic patientsJ Clin Endocrinol Metab2007921249125517244786
   PubMed Web of Science ®Google Scholar
• FoleyJEJordanJWeight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experienceVasc Health Risk Manag2010654154820730070
   PubMedGoogle Scholar
• AhrenBFoleyJEBosiEClinical evidence and mechanistic basis for vildagliptin’s action when added to metforminDiabetes Obes Metab20111319320321205107
   PubMed Web of Science ®Google Scholar
• MatthewsDRDejagerSAhrenBVildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year studyDiabetes Obes Metab20101278078920649630
   PubMed Web of Science ®Google Scholar
• FerranniniEFonsecaVZinmanBFifty-two-week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapyDiabetes Obes Metab20091115716619125777
   PubMed Web of Science ®Google Scholar
• AhrenBSchweizerADejagerSVillhauerEBDunningBEFoleyJEMechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humansDiabetes Obes Metab20111377578321507182
   PubMed Web of Science ®Google Scholar
• MathieuCBarnettAHBrathHEffectiveness and tolerability of oral glucose-lowering therapies in type 2 diabetes: a real-life worldwide observational study (EDGE)Int J Clin Pract20136794795623961850
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation 2013IDF Diabetes Atlas6th ed Available from: http://www.idf.org/diabetesatlas/data-visualisationsAccessed March 4, 2014
   Google Scholar
• MendivilCOMárquez-RodríguezEAngelIDComparative effectiveness of vildagliptin in combination with other oral anti-diabetes agents in usual-care conditions: the EDGE-Latin America studyCurr Med Res Opin2014301769177624867177
   PubMed Web of Science ®Google Scholar
• WangnooSKBaderGGawaiASinghSEffectiveness and tolerability of vildagliptin in Indian patients with type 2 diabetes mellitus: results from EDGE – a real-world observational studyIndian J Clin Pract201324537642
   Google Scholar
• ZabetianAKeliHMEchouffo-TcheuguiJBNarayanKMAliMKDiabetes in the Middle East and North AfricaDiabetes Res Clin Pract201310110612223642969
   PubMed Web of Science ®Google Scholar
• Al-MaskariFEl-SadigMAl-KaabiJMKnowledge, attitude and practices of diabetic patients in the United Arab EmiratesPLoS One20138e5285723341913
   PubMed Web of Science ®Google Scholar
• GökeRBaderGDworakMReal-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in GermanyDiabetes Ther2014518319124643724
   PubMed Web of Science ®Google Scholar
• NilssonPMBrathHPenfornisAReal life effectiveness and safety of vildagliptin compared with other OADs in European type 2 diabetes mellitus patients: results from the EDGE studyDiabetologia201457Suppl 1S1S366
   Google Scholar
• AhrénBMathieuCBaderGSchweizerAFoleyJEEfficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studiesDiabetologia2014571304130724682379
   PubMed Web of Science ®Google Scholar
• MirzazadehABaradaranHRHaghdoostAASalariPRelated factors to disparity of diabetes care in IranMed Sci Monit200915PH32PH3619396047
   PubMed Web of Science ®Google Scholar
• MahfouzEMAwadallaHICompliance to diabetes self-management in rural El-Mina, EgyptCent Eur J Public Health201119354121526654
   PubMed Web of Science ®Google Scholar
• Ligueros-SaylanMFoleyJESchweizerACouturierAKothnyWAn assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trialsDiabetes Obes Metab20101249550920518805
   PubMed Web of Science ®Google Scholar
• SchweizerADejagerSFoleyJECouturierALigueros-SaylanMKothnyWAssessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes populationDiabetes Obes Metab20101248549420518804
   PubMed Web of Science ®Google Scholar
• RathmannWKostevKGruenbergerJBDworakMBaderGGianiGTreatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysisDiabetes Obes Metab201315556122862879
   PubMed Web of Science ®Google Scholar
• Al-AroujMHassounAAMedlejRThe effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE studyInt J Clin Pract20136795796324001317
   PubMed Web of Science ®Google Scholar
• HassounAAl-AroujMIbrahimMThe effect of vildagliptin relative to sulphonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan in the Middle East: the VIRTUE study Available from: http://www.researchgate.net/publication/259389442_The_First_Clinical_Congress_of_the_Gulf_Chapter_of_the_American_Association_of_Clinical_Endocrinologists_October_3_rd_-5_th_2013_St_Regis_Hotel_Abu_Dhabi_United_Arab_EmiratesAccessed January 8, 2015
   Google Scholar